학술논문
Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells.
Document Type
Editorial & Opinion
Author
Mazza R; Leucid Bio Ltd., Guy's Hospital, London, UK.; Maher J; Leucid Bio Ltd., Guy's Hospital, London, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.; Department of Immunology, Eastbourne Hospital, Eastbourne, UK.; Hull CM; Leucid Bio Ltd., Guy's Hospital, London, UK.
Source
Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2218-6751
Abstract
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-793/coif). C.M.H. and R.M. are employees of Leucid Bio Ltd. J.M. is the founder, Chief Scientific Officer and shareholder of Leucid Bio Ltd. The authors have no other conflicts of interest to declare.